Ken Griffin significantly reduced his stake in Palantir Technologies while increasing his investment in Biogen.
Griffin's timing in selling Palantir may have been poor, as its value has since doubled.
Despite heavy investment in Biogen, it is currently performing poorly within Griffin's portfolio.